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Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is increasingly used in
bi-ventricular failure with cardiogenic shock to maintain systemic perfusion. Nonetheless,
it tends to increase left ventricular (LV) afterload and myocardial oxygen demand. In
order to mitigate these negative effects on the myocardium, an Impella CP® (3.5 L/min
Cardiac Output) can be used in conjunction with V-A ECMO (ECMELLA approach).
We implemented this strategy in a patient with severe acute myocarditis complicated
by cardiogenic shock. Due to a hemolysis crisis, Impella CP® had to be substituted
with PulseCath iVAC2L®, which applies pulsatile flow to unload the LV. A subsequent
improvement in LV systolic function was noted, with increased LV ejection fraction (LVEF),
LV end-diastolic diameter (LVEDD) reduction, and a reduction in plasma free hemoglobin.
This case documents the efficacy of iVAC2L in replacing Impella CP as a LV vent during
V-A ECMO, with less hemolysis.
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INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) is one of the most utilized mechanical circulatory
support (MCS) modalities in patients with cardiogenic shock (1). Nonetheless, a major
disadvantage of peripheral veno-arterial (V-A) ECMO is the risk of increased left-heart filling
pressures, especially in patients with highly reduced ejection fractions (EFs) (2).
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The principles of PulseCath iVAC2L (PulseCath BV,
Amsterdam, The Netherlands) have been described previously
(3, 4). iVAC2L is a novel pulsatile circulatory support system
capable of generating an output of up to 2.0 L/min (3). It
can be used as a left ventricular (LV) assist device in cases
of LV dysfunction due to acute myocardial infarction, as
well as in acute heart failure (HF) post-cardiac surgery
(3). While the Impella system (Abiomed, Danvers, MA,
USA) is extremely useful for LV unloading (5, 6), it is
associated with increased risk of hemolysis due to the use
of continuous flow (7–10). Hemolysis has been associated
with worse prognosis following MCS (11, 12) and commonly
motivates device explantation when found in uncontrollable
and severe levels. It is unknown whether the replacement
of an Impella with an iVAC2L can produce a benefit in
terms of reduced hemolysis with comparable LV unloading.
The latter is of particular interest, since it had been shown
that an Impella-based LV unloading can exert additional
anti-inflammatory disease-modifying effects when used as
bridge to recovery in severe myocarditis (4, 5). The efficacy of a
combination of iVAC2Lwith V-A ECMO inmyocarditis-induced
biventricular cardiogenic shock scenario has not been studied
to date.
CASE REPORT
A 49-years-old man of Asian background has been hospitalized
at our institution for cardiogenic shock due to acute lymphocytic
myocarditis, which was diagnosed by endomyocardial biopsy
(Figure 1). Connected to an Impella CP and on high
catecholamine doses, the patient was transported from a
peripheral hospital to our institution. At admission, the patient
presented with lactate > 100 mg/dl, lactate dehydrogenase
(LDH) of 1,077 U/L, troponin T of 14,896 ng/L, creatine
kinase of 1,590 U/L, and N-terminal pro b-type natriuretic
peptide (NT-proBNP) of 2,399 ng/L. Since kidney function
was impaired with anuria and a serum creatinine of 1.62
mg/dl, dialysis had to be started. On high catecholamine doses,
LVEF was around 5%, while right ventricular function was
visually at least moderately depressed. The cardiac index was
1.3 L/min/m2 with a pulmonary capillary wedge pressure of
around 40 mmHg. We then started a V-A ECMO to obtain
hemodynamic stabilization (ECMELLA-approach). After 6
days of ECMELLA, hemolysis increased significantly with
plasma free hemoglobin (fHb) reaching levels above 130 mg/dl
(20 µmol/L) despite reduction of the Impella CP support.
To continue venting the LV, we decided to substitute Impella
CP with PulseCath iVAC2L. A 30-cm-long, 18-Fr Adelante R©
Magnum (Oscor Inc.) sheath was inserted in the femoral
artery, which had been used for the Impella access. The side
port from the Adelante R© was connected by sideline with the
pressure transducer from the intra-aortic balloon pump (IABP)
console. After iVAC2L was inserted with the distal tip into
the LV cavity, the paracorporeal membrane pump was filled
with heparinized saline, and a wet-to-wet connection was
FIGURE 1 | Histology (A) as well as immunohistological findings (B) in left
ventricular endomyocardial biopsies illustrate a severe lymphocytic myocarditis
with myocyte necrosis (blue circles) and infiltration of invading inflammatory
cells (brown infiltrates).
established with the iVAC2L catheter (Supplementary Movie 1).
A CS100 IABP console (Maquet Cardiovascular, Fairfield, NJ,
USA) was used as a driver, and triggering was done using the
aortic pressure (AP) waveform (Figure 2A). The console was
set to synchronized mode and 1:1 assist ratio. Anticoagulation
was provided with partial thromboplastin time (PTT) of 80 s
during MCS.
The main results obtained were the following: increase in
LVEF from 10% to about 20%, reduction in fHb to <10 µmol/L
(65 mg/dl), reduction of the LV end-diastolic diameter (LVEDD)
from 67 to 64mm, and stabilization of the blood pressure in
110/60 mmHg, allowing for the reduction of the ECMO support
to a minimum. There was a moderate acute reduction on LV
end-diastolic pressure (LVEDP) from 22 to 18 mmHg. This
was added to afterload reduction and increase in forward flow,
which were evidenced by distal displacement of the watershed
as contrast media became visible in the descending aorta
(Figures 2B,C).
After 5 days of pulsatile support, the membrane pump, the
connector tubing, and the bi-directional flow catheter were
inspected, revealing no signs of thrombus formation, component
disruption, or fatigue. Weaning of iVAC2L was performed
according to the following steps: synchronized pulsatile flow with
1:1 assist ratio for 5 days, 1:2 for 8 h, and 1:3 for further 8 h.
Hemodynamic stability without catecholamine support, central
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FIGURE 2 | (A) IABP console during LV unloading with V-A-ECMO and iVAC2L. The diastolic pressure drop in the aortic pressure (green arrows) is attenuated as
pressure increases in the gas chamber of iVAC2L (bottom waveform in blue). LV blood aspirated during systole is then ejected back in the ascending aorta. When the
pressure falls in the gas chamber, ejection stops and aortic pressure quickly drops. The magnitude of the attenuation in the pressure drop may oscillate between
successive beats due to transitory variations in myocardial conduction, mechanics and loading conditions generated by extra-systoles, arrhythmias or changes in
intrathoracic pressure. (B) Aortography showing a watershed line around the left subclavian artery during 3.5 L/min V-A ECMO. (C) In the 5th heart beat following
iVAC2L activation, the watershed line moved to the descending aorta demonstrating a decrease in afterload despite V-A ECMO support. Red circle: two-way valve
(outlet) positioned next to the coronary ostia; red arrow: distal tip if the iVAC system in the left ventricle; green arrow: pigtail catheter.
FIGURE 3 | (A) Illustration of iVAC2L positioned inside the left ventricle. Blood is aspirated through the inlet to the membrane pump during systole and ejected in the
ascending aorta through the proximally located outlet valve. (B) Technical details of iVAC2L including the bi-directional catheter and the membrane pump.
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venous oxygen saturation (SvO2) > 60%, and normal lactate
levels were observed throughout the weaning period. iVAC2L
was set to standby mode and removed under low-dose inotropic
support (dobutamine 2 µg/kg/min).
DISCUSSION
This is the first report on V-A ECMO describing the
conversion of LV venting strategy from continuous flow
(Impella CP) to pulsatile flow (iVAC2L, EC-iVAC R© approach;
Supplementary Movie 1) as an instrumental tool in reducing
hemolysis levels during V-A ECMO.
The estimated frequency of ECMO-related hemolysis with
fHb > 50 mg/dl is 12% in adults and 67% in patients
< 19 years old. fHb promotes oxidative stress, leading to
apoptosis and inflammation at tissue level. Once established,
hemolysis may lead to acute kidney failure, thrombocytopenia,
and reduced survival. Therefore, it should be avoided as much as
possible (11–13).
The iVAC system is driven by a standard IABP console
and does not require dedicated software. It relies on counter-
pulsation similarly to the IABP but has the advantage of
actively creating forward flow regardless of the innate LV
function. LV blood is aspirated to the blood chamber in
systole, to be ejected back into the ascending aorta in
diastole (Figure 3).
Compared with continuous flow devices, this approach
has the potential to spare the native LV during systole by
reducing the afterload while actively creating forward flow.
The outlet is located close to the coronary ostia, where it
promotes diastolic augmentation, potentially optimizing
the myocardial oxygen supply/demand ratio. Furthermore,
continuous flow has been related with loss of arterial
compliance as a consequence of persistent stiffening of the
vascular walls. In a pilot study prospectively enrolling 14
individuals referred for high-risk percutaneous coronary
intervention (PCI) under MCS, den Uil et al. described
intra-procedural increases in mean arterial pressure, cardiac
output, and SvO2 with iVAC2L (7). The upcoming PULSE trial
(NCT03200990), a mechanistic exploratory study addressing
the hemodynamic performance of iVAC2L vs. Impella CP, will
provide further information on the hemodynamic effects of
iVAC2L (2, 3, 14).
Previous reports were focused on iVAC3L, a 21-Fr surgically
implanted version of the iVAC system. In 2007, Mariani et al.
described its use in 14 patients undergoing off-pump coronary
artery bypass surgery (CABG), resulting in an average fHb of
112 ± 40 mg/dl (17 ± 6 µmol/L) (3). In a second report,
Anastasiadis et al. described the use of iVAC3L as LV vent during
V-A ECMO. The patient was a 33-years-old male receiving V-A
ECMO due to profound cardiogenic shock that was secondary to
an acute anterior myocardial infarction. iVAC3L was implanted
on the first postoperative day. Despite an initial period of
hemodynamic improvement, V-A ECMO had to be added due
to subsequent clinical and hemodynamic deterioration. iVAC3L
was kept in place, and both devices were weaned after 10
days. The mean fHb was 100 mg/dl (16 µmol/L), with the
highest levels being recorded in the first 48 h after the start of
ECMO (3).
In the two reports mentioned above, iVAC3L was applied
during or immediately after two major cardiovascular
interventions that are well-known to cause hemolysis. As a
result, the reported levels of fHb were higher. Similarly, the
increase in fHb in our case was of substantial magnitude as
a result of the combination of V-A ECMO with a continuous
flow device. This occurred in a patient with low body weight,
which is an additional predisposing factor for hemolysis (11).
Notwithstanding, the marked reduction in fHb that followed
the substitution of Impella with iVAC2L suggests that ECMO
was not the main causative factor of the hemolytic crisis. When
used alone in high-risk PCI, iVAC2L had a median peak fHb of
39 mg/dl (10 µmol/L) (3), which is lower than values already
reported with Impella 2.5 (7).
In conclusion, iVAC2L was easy to handle during
implantation and positioning. It provided pulsatile support
for 5 days without requiring any replacements or corrections
and resulted in less hemolysis than Impella CP. iVAC2L may be
an alternative when other LV venting systems are not available
or when complications occur. This case is a proof of concept
for potential future applications and a bridging tool supporting
clinical decision making, which may help to improve and
personalize patient management in complex cardiovascular
diseases. A prospective, randomized study is needed to further
investigate this approach.
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